Article Figures & Data
Figures
- Figure 1.
Effects of Rivaroxaban and Vitamin K Antagonists on Time to Cardioversion
VKA, vitamin K antagonist; INR, international normalized ratio. a Reason for not performing cardioversion as first scheduled from 21–25 days primarily due to inadequate anticoagulation (indicated by drug compliance <80% for rivaroxaban or weekly INRs outside the range of 2.0–3.0 for 3 consecutive weeks before cardioversion for VKA).
Reproduced with permission from R Cappato, MD.
Tools
X-VeRT Results: Rivaroxaban is Safe and Effective for Cardioversion in AF
Permalink:
Table of contents
Cited By...
- No citing articles found.